March 26, 2025 10:10 AM EDT
News Briefing

Hu­ma­cyte to raise $50M; Acrivon to fo­cus on prex­as­ert­ib in en­dome­tri­al can­cer

ENDPOINTS

Plus, news about Tri­bune Ther­a­peu­tics and Leap Ther­a­peu­tics:

Hu­ma­cyte’s $50M of­fer­ing: The North Car­oli­na biotech is sell­ing 25 mil­lion shares at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

A service from the Financial Times